Use of Factor VIIa and Anti-inhibitor Coagulant Complex in Pediatric Cardiac Surgery Patients
Both rFVIIa and FEIBA reduced blood product usage in pediatric patients following cardiac procedures.
World's Largest Resource for Cardiovascular Perfusion
Both rFVIIa and FEIBA reduced blood product usage in pediatric patients following cardiac procedures.
SACP attenuates the metabolic changes seen after HCA. Further studies are required to assess optimal perfusion conditions and clinical outcome.
Conventional CABG is responsible for deterioration in [O2Hb], and CBV, which peak at 40–60 min following initiation of CPB. The changes in [O2Hb] are reversible whereas the reduction of CBV persists to the end of the surgery.